

## APC/Cyanine7 anti-mouse CD4 Antibody

<b>Catalog# / Size</b>	100413 / 25 µg 100414 / 100 µg
<b>Clone</b>	GK1.5
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	L3T4, T4
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse CTL clone V4
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: blocking of CD4 <sup>+</sup> T cell activation <sup>1,4,11</sup> , thymocyte costimulation <sup>3</sup> , <i>in vitro</i> and <i>in vivo</i> depletion <sup>2,5-8</sup> , blocking of egg-sperm cell adhesion <sup>1,4</sup> , immunohistochemical staining of acetone-fixed frozen sections <sup>9,10</sup> , immunoprecipitation <sup>1,2</sup> , and spatial biology (IBEX) <sup>12,13</sup> . The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).
<b>Additional Product Notes</b>	BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact <a href="#">Technical Service</a> if you have any questions.
<b>Application References</b>	<ol style="list-style-type: none"> <li>Dialynas DP, <i>et al.</i> 1983. <i>J. Immunol.</i> 131:2445. (Block, IP)</li> <li>Dialynas DP, <i>et al.</i> 1983. <i>Immunol. Rev.</i> 74:29. (IP, Deplete)</li> <li>Wu L, <i>et al.</i> 1991. <i>J. Exp. Med.</i> 174:1617. (Costim)</li> <li>Godfrey DI, <i>et al.</i> 1994. <i>J. Immunol.</i> 152:4783. (Block)</li> <li>Gavett SH, <i>et al.</i> 1994. <i>Am. J. Respir. Cell. Mol. Biol.</i> 10:587. (Deplete)</li> <li>Schuyler M, <i>et al.</i> 1994. <i>Am. J. Respir. Crit. Care Med.</i> 149:1286. (Deplete)</li> <li>Ghobrial RR, <i>et al.</i> 1989. <i>Clin. Immunol. Immunopathol.</i> 52:486. (Deplete)</li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

8. Israelski DM, *et al.* 1989. *J. Immunol.* 142:954. (Deplete)
9. Zheng B, *et al.* 1996. *J. Exp. Med.* 184:1083. (IHC)
10. Frei K, *et al.* 1997. *J. Exp. Med.* 185:2177. (IHC)
11. Felix NJ, *et al.* 2007. *Nat. Immunol.* 8:388. (Block)
12. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
13. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Liu Y, *et al.* 2021. *Cell Metabolism.* 33(6):1221-1233.e11. [PubMed](#)
2. Strickley JD, *et al.* 2019. *Nature.* 575:519. [PubMed](#)
3. Vasanthakumar A, *et al.* 2020. *Nature.* 579:581. [PubMed](#)
4. Bergot AS, *et al.* 2020. *J Immunol.* 204:1787. [PubMed](#)
5. Boyd DF, *et al.* 2020. *Nature.* 587:466. [PubMed](#)
6. Viny AD, *et al.* 2019. *Cell Stem Cell.* 25:682. [PubMed](#)
7. Hirata Y *et al.* 2018. *Cell stem cell.* 22(3):445-453. [PubMed](#)
8. Li H, *et al.* 2022. *Cell Rep Med.* 3:100554. [PubMed](#)
9. Li Q, *et al.* 2022. *Cell Rep.* 40:111308. [PubMed](#)
10. Fan L, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
11. Dong L, *et al.* 2021. *Cancer Cell.* . [PubMed](#)
12. Shao B, *et al.* 2018. *Mol Med Rep.* 18:920. [PubMed](#)
13. Farsakoglu Y *et al.* 2019. *Cell reports.* 26(9):2307-2315. [PubMed](#)
14. Aldon Y, *et al.* 2020. *J Immunol.* 204:903. [PubMed](#)
15. Pandey S, *et al.* 2020. *Cell Syst.* 11:495. [PubMed](#)
16. Chen J, *et al.* 2021. *Sci Adv.* 7:. [PubMed](#)
17. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
18. Andreas N, *et al.* 2021. *Arthritis Res Ther.* 23:222. [PubMed](#)
19. Wang Q, *et al.* 2020. *Wound Repair Regen.* 28:105. [PubMed](#)
20. Saito S, *et al.* 2020. *Nutrients.* 12:. [PubMed](#)
21. Lutes LK, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
22. Wang X, *et al.* 2021. *Front Cell Dev Biol.* 632805:9. [PubMed](#)
23. Petursdottir D, *et al.* 2017. *Front Immunol.* . 10.3389/fimmu.2017.01699. [PubMed](#)
24. Pérez-Maziah D *et al.* 2017. *EBioMedicine.* 24:216-230. [PubMed](#)
25. Treger RS, *et al.* 2020. *Immunity.* 50(2):334-347.e9.. [PubMed](#)
26. Inoue D, *et al.* 2021. *Nat Genet.* 53:707. [PubMed](#)
27. Tu X, *et al.* 2022. *Nat Commun.* 13:6977. [PubMed](#)
28. Ciarlo E, *et al.* 2016. *Sci Rep.* 6:37944. [PubMed](#)
29. Markov SD, *et al.* 2021. *Mol Cancer Ther.* 20:2457. [PubMed](#)
30. Ontiveros-Padilla L, *et al.* 2021. *Microorganisms.* 9:. [PubMed](#)
31. Mizraji\* G, *et al.* 2013. *J Vis Exp.* 77: 50388. [PubMed](#)
32. Collinson-Pautz M, *et al.* 2016. *PLoS One.* 11:e0164547. [PubMed](#)
33. Kunimoto H, *et al.* 2018. *Cancer Cell.* 33:44. [PubMed](#)
34. Yu X, *et al.* 2022. *J Extracell Vesicles.* 11:e12185. [PubMed](#)
35. Wilson AS, *et al.* 2022. *Nat Commun.* 13:528. [PubMed](#)
36. Feng H, *et al.* 2020. *J Dermatol.* 47:147. [PubMed](#)
37. Levi J, *et al.* 2020. *J Nucl Med.* . [PubMed](#)
38. Poczobutt J, *et al.* 2016. *J Immunol.* 196: 891 - 901. [PubMed](#)
39. Holvoet B, *et al.* 2015. *Stem Cell Reports.* 5: 1183-1195. [PubMed](#)
40. Chun E, *et al.* 2020. *Immunity.* 51(5):871-884.e6.. [PubMed](#)
41. Wang GZ, *et al.* 2019. *Nat Commun.* 10:1125. [PubMed](#)
42. Kleppe M *et al.* 2018. *Cancer cell.* 33(1):29-43. [PubMed](#)
43. Levescot A, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
44. Venturutti L, *et al.* 2020. *Cell.* 182(2):297-316.e27. [PubMed](#)
45. Ma W, *et al.* 2017. *Sci Rep.* . 10.1038/s41598-017-15661-6. [PubMed](#)
46. Schadt L, *et al.* 2020. *Cell Reports.* 29(5):1236-1248.e7.. [PubMed](#)
47. Shi R, *et al.* 2022. *Theranostics.* 12:875. [PubMed](#)
48. Gary E, *et al.* 2020. *Vaccine.* 3821:38. [PubMed](#)
49. Zhang C, *et al.* 2020. *Cell Rep.* 32:108206. [PubMed](#)
50. St Clair JB, *et al.* 2017. *PLoS One.* 12:e0170556. [PubMed](#)
51. Wennerberg E, *et al.* 2022. *Sci Transl Med.* 14:eabe8195. [PubMed](#)
52. Hum NR, *et al.* 2022. *Front Oncol.* 12:928474. [PubMed](#)
53. Mara AB, *et al.* 2022. *NPJ Vaccines.* 7:86. [PubMed](#)
54. Zeng Q, *et al.* 2022. *Front Immunol.* 13:740805. [PubMed](#)
55. Zhang L, *et al.* 2021. *Clin Transl Med.* 11:e464. [PubMed](#)
56. Vaena S, *et al.* 2021. *Cell Reports.* 35(5):109076. [PubMed](#)
57. Cheng Y, *et al.* 2019. *Clin Cancer Res.* 25:2621. [PubMed](#)
58. Kräutler NJ, *et al.* 2020. *Cell Reports.* 30(4):997-1012.e6.. [PubMed](#)
59. Liang J, *et al.* 2020. *Sci Adv.* 6:eabc3646. [PubMed](#)
60. Jorapur A, *et al.* 2022. *PLoS Pathog.* 18:e1010200. [PubMed](#)
61. Dey S, *et al.* 2020. *J Immunother Cancer.* 8:. [PubMed](#)
62. Lee L, *et al.* 2016. *PLoS One.* 11:e0167693. [PubMed](#)
63. Pham D, *et al.* 2019. *Cell Rep.* 29:1203. [PubMed](#)
64. Brown SM *et al.* 2017. *Endocrinology.* 158(10):3592-3604. [PubMed](#)
65. Sydney Lavoie *et al.* 2019. *eLife.* 8 pii: e39982. [PubMed](#)
66. Chatterjee S *et al.* 2017. *Cell metabolism.* 27(1):85-100. [PubMed](#)
67. Yang S, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
68. Ding P, *et al.* 2022. *Bone Res.* 10:42. [PubMed](#)
69. Perry JL, *et al.* 2020. *ACS Nano.* 5.583333333. [PubMed](#)
70. Sadik A, *et al.* 2020. *Cell.* 1252:182. [PubMed](#)
71. Merlo LM, *et al.* 2020. *Clin Pathol.* 13:2632010X20951812. [PubMed](#)

72. Ryan NM, *et al.* 2022. *Front Immunol.* 13:932742. [PubMed](#)
73. Zeng Q, *et al.* 2022. *iScience.* 25:105151. [PubMed](#)
74. Yeung F, *et al.* 2020. *Cell Host & Microbe.* 27(5):809-822. [PubMed](#)
75. Ouyang S, *et al.* 2019. *J Immunol.* 202:1441. [PubMed](#)
76. Matsumura T, *et al.* 2022. *Nat Commun.* 13:7064. [PubMed](#)
77. Li M, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
78. Dong X, *et al.* 2022. *Front Immunol.* 13:896472. [PubMed](#)
79. Bent EH, *et al.* 2021. *Nat Commun.* 12:6218. [PubMed](#)
80. Murdock BJ, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
81. Zhang H, *et al.* 2021. *Cell Reports.* 35(6):109096. [PubMed](#)
82. Kang YH, *et al.* 2019. *Nat Commun.* 10:912. [PubMed](#)
83. Dallari S, *et al.* 2021. *Cell Host Microbe.* 29(6):1014-1029.e8. [PubMed](#)
84. McNamee E, *et al.* 2013. *Gut.* 62:53. [PubMed](#)
85. Zhao N, *et al.* 2018. *J Clin Invest.* 26:84. [PubMed](#)
86. Wang X, *et al.* 2021. *Cell.* 184:5357. [PubMed](#)
87. Molina MS, *et al.* 2021. *Front Immunol.* 12:699128. [PubMed](#)
88. Jeon Y, *et al.* 2015. *PLoS One.* 10: e0139845. [PubMed](#)
89. Montes de Oca M, *et al.* 2016. *PLoS Pathog.* 12: 1005398. [PubMed](#)
90. Di Pilato M, *et al.* 2021. *Cell.* 184(17):4512-4530.e22. [PubMed](#)
91. Porrello A, *et al.* 2018. *Nat Commun.* 9:1988. [PubMed](#)
92. Sade-Feldman M, *et al.* 2018. *Cell.* 175:998. [PubMed](#)
93. Field CS, *et al.* 2020. *Cell Metab.* 31:422. [PubMed](#)
94. Le QV, *et al.* 2022. *Bioact Mater.* 15:160. [PubMed](#)
95. Ma C, *et al.* 2021. *J Exp Med.* :218. [PubMed](#)
96. Wang M, *et al.* 2021. *iScience.* 24(7):102766. [PubMed](#)
97. Sheng J, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
98. Chen S, *et al.* 2015. *Cancer Res.* 7: 519-531. [PubMed](#)
99. Liang Z, *et al.* 2017. *Autophagy.* 14:505. [PubMed](#)
100. Luo H, *et al.* 2019. *Cell Rep.* 26:945. [PubMed](#)
101. Tippimanchai DD, *et al.* 2018. *Oncoimmunology.* 7:e1438105. [PubMed](#)
102. Chen B, *et al.* 2021. *Cell.* 184:6262. [PubMed](#)
103. Wang X, *et al.* 2022. *Elife.* 11:. [PubMed](#)
104. Sen D, *et al.* 2016. *PLoS One.* 11:e0165064. [PubMed](#)
105. Young JS, *et al.* 2018. *Front Immunol.* 9:1385. [PubMed](#)
106. Li A, *et al.* 2018. *Cancer Lett.* 431:54. [PubMed](#)
107. Liu A, *et al.* 2022. *Front Cell Infect Microbiol.* 12:960208. [PubMed](#)
108. Dai B, *et al.* 2021. *Cell Reports Medicine.* 2(8):100381. [PubMed](#)
109. Xiang W, *et al.* 2020. *Signal Transduct Target Ther.* 0.374305556. [PubMed](#)
110. Ma C, *et al.* 2020. *Sci Adv.* 6:eaz6717. [PubMed](#)
111. Wolf Y, *et al.* 2019. *Cell.* 179:219. [PubMed](#)
112. Ershaid N, *et al.* 2019. *Nat Commun.* 10:4375. [PubMed](#)
113. Chen S, *et al.* 2018. *Nat Commun.* 9:5298. [PubMed](#)
114. Liang Z, *et al.* 2022. *iScience.* 25:105233. [PubMed](#)
115. Li H, *et al.* 2021. *Signal Transduct Target Ther.* 6:389. [PubMed](#)
116. Chang MH, *et al.* 2021. *Cell Rep.* 37:109902. [PubMed](#)

**RRID** AB\_312698 (BioLegend Cat. No. 100413)  
 AB\_312699 (BioLegend Cat. No. 100414)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, 55 kD
<b>Distribution</b>	Majority of thymocytes, T cell subset
<b>Function</b>	TCR co-receptor, T cell activation
<b>Ligand/Receptor</b>	MHC class II molecule
<b>Cell Type</b>	Dendritic cells, T cells, Thymocytes, Tregs
<b>Biology Area</b>	Immunology
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Bierer BE, <i>et al.</i> 1989. <i>Annu. Rev. Immunol.</i> 7:579.</li> <li>3. Janeway CA. 1992. <i>Annu. Rev. Immunol.</i> 10:645.</li> </ol>
<b>Gene ID</b>	<a href="#">12504</a>


## Related Protocols

---

## Other Formats

APC anti-mouse CD4, Biotin anti-mouse CD4, FITC anti-mouse CD4, PE anti-mouse CD4, PE/Cyanine5 anti-mouse CD4, Purified anti-mouse CD4, PE/Cyanine7 anti-mouse CD4, APC/Cyanine7 anti-mouse CD4, Alexa Fluor® 647 anti-mouse CD4, Alexa Fluor® 488 anti-mouse CD4, Pacific Blue™ anti-mouse CD4, Alexa Fluor® 700 anti-mouse CD4, PerCP anti-mouse CD4, PerCP/Cyanine5.5 anti-mouse CD4, Brilliant Violet 421™ anti-mouse CD4, Ultra-LEAF™ Purified anti-mouse CD4, Alexa Fluor® 594 anti-mouse CD4, Brilliant Violet 711™ anti-mouse CD4, Brilliant Violet 510™ anti-mouse CD4, Brilliant Violet 605™ anti-mouse CD4, Brilliant Violet 785™ anti-mouse CD4, PE/Dazzle™ 594 anti-mouse CD4, APC/Fire™ 750 anti-mouse CD4, GoInVivo™ Purified anti-mouse CD4, Brilliant Violet 750™ anti-mouse CD4, Brilliant Violet 650™ anti-mouse CD4, Spark Blue™ 550 anti-mouse CD4, Spark NIR™ 685 anti-mouse CD4, KIRAVIA Blue 520™ anti-mouse CD4, PE/Fire™ 640 anti-mouse CD4, APC/Fire™ 810 anti-mouse CD4, PE/Fire™ 700 anti-mouse CD4, Spark Violet™ 538 anti-mouse CD4, Spark YG™ 593 anti-mouse CD4, Spark Blue™ 574 anti-mouse CD4 Antibody, Spark UV™ 387 anti-mouse CD4

## Product Data



C57BL/6 mouse splenocytes were stained with CD3 FITC and CD4 (clone GK1.5) APC/Cyanine7 (left) or Rat IgG2b, κ isotype control (right).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587